{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(20)"],"submitter":["Camus V"],"pubmed_abstract":["<h4>Abstract</h4>Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is debated. We analyzed patients with large B-cell lymphoma in the DESCAR-T registry treated with axi[1]cel or tisa-cel in ≥3rd line and TAFA-LEN before (n = 15, \"TL-pre-CAR-T\" set) or directly after (n = 52, \"TL-post-CAR-T\" set) CAR T-cell therapy. We compared TAFA-LEN v. other treatments using inverse probability weighting in the TL-post-CAR[1]T set. In the TL-post-CAR-T set, the median progression-free survival (mPFS), overall survival (mOS), and duration of response (mDOR) since the first treatment for progression (mPFS2/mOS2/mDOR2) were 3, 4.7, and 8.1 months, respectively. The best overall response rate (bORR) and best complete response r"],"journal":["Blood advances"],"pagination":["5371-5381"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11568786"],"repository":["biostudies-literature"],"pubmed_title":["Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy."],"pmcid":["PMC11568786"],"pubmed_authors":["Carras S","Castilla-Llorente C","Chauchet A","Abraham J","Houot R","Drieu La Rochelle L","Casasnovas O","Marquet A","Tounes L","Oberic L","Damaj GL","Bailly S","Decroocq J","Jardin F","Guidez S","Dupont V","Fornecker LM","Lemonnier F","Herbaux C","Hermine O","Morschhauser F","Le Gouill S","Sesques P","Campidelli A","Joris M","Brisou G","Bouabdallah K","Paillassa J","Choquet S","Tessoulin B","Krzisch D","Camus V"],"additional_accession":[]},"is_claimable":false,"name":"Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy.","description":"<h4>Abstract</h4>Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is debated. We analyzed patients with large B-cell lymphoma in the DESCAR-T registry treated with axi[1]cel or tisa-cel in ≥3rd line and TAFA-LEN before (n = 15, \"TL-pre-CAR-T\" set) or directly after (n = 52, \"TL-post-CAR-T\" set) CAR T-cell therapy. We compared TAFA-LEN v. other treatments using inverse probability weighting in the TL-post-CAR[1]T set. In the TL-post-CAR-T set, the median progression-free survival (mPFS), overall survival (mOS), and duration of response (mDOR) since the first treatment for progression (mPFS2/mOS2/mDOR2) were 3, 4.7, and 8.1 months, respectively. The best overall response rate (bORR) and best complete response r","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-06-03T03:12:10.748Z","creation":"2025-04-06T22:45:57.644Z"},"accession":"S-EPMC11568786","cross_references":{"pubmed":["39163620"],"doi":["10.1182/bloodadvances.2024013726"]}}